Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma: An Evidence Review Group Evaluation of the NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE), as part of the institute’s single technology appraisal (STA) process, invited the company that makes obinutuzumab (Roche Products Limited) to submit evidence of the clinical and cost effectiveness of the drug in combination with chemother...

Descripción completa

Detalles Bibliográficos
Autores principales: Thielen, Frederick W., Büyükkaramikli, Nasuh C., Riemsma, Rob, Fayter, Debra, Armstrong, Nigel, Wei, Ching-Yun, Huertas Carrera, Vanesa, Misso, Kate, Worthy, Gill, Kleijnen, Jos, Corro Ramos, Isaac
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598743/
https://www.ncbi.nlm.nih.gov/pubmed/30547368
http://dx.doi.org/10.1007/s40273-018-0740-4

Ejemplares similares

Ejemplares similares